BIOCRYST PHARMACEUTICALS INC

NASDAQ: BCRX (BioCryst Pharmaceuticals, Inc.)

最近更新时间: 3天之前, 3:09PM

9.36

-0.30 (-3.11%)

前收盘价格 9.66
收盘价格 10.05
成交量 7,448,509
平均成交量 (3个月) 4,644,987
市值 1,958,579,968
预期市盈率 (P/E Forward) 53.48
价格/销量 (P/S) 3.88
股市价格/股市净资产 (P/B) 56.59
52周波幅
6.02 (-35%) — 11.31 (20%)
利润日期 4 Aug 2025 - 8 Aug 2025
营业毛利率 -10.62%
营业利益率 (TTM) 14.59%
稀释每股收益 (EPS TTM) -0.260
季度收入增长率 (YOY) 56.90%
流动比率 (MRQ) 2.93
营业现金流 (OCF TTM) -25.85 M
杠杆自由现金流 (LFCF TTM) 42.90 M
资产报酬率 (ROA TTM) 4.54%

市场趋势

短期 中期
行业 Biotechnology (US) 看跌 看跌
Biotechnology (全球的) 看跌 看跌
股票 BioCryst Pharmaceuticals, Inc. 看涨 看涨

AIStockmoo 评分

0.4
分析师共识 5.0
内部交易活动 NA
价格波动 -0.5
技术平均移动指标 -2.5
技术振荡指标 -0.5
平均 0.38

相关股票

股票 市值 DY P/E(TTM) P/B
BCRX 2 B - - 56.59
EXEL 12 B - 19.94 5.51
CORT 8 B - 66.76 11.91
HALO 6 B - 13.87 13.34
TGTX 6 B - 143.80 24.96
ACAD 4 B - 15.74 4.84

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

部门 Healthcare
行业 Biotechnology
投资方式 Small Growth
内部持股比例 1.20%
机构持股比例 85.56%
52周波幅
6.02 (-35%) — 11.31 (20%)
目标价格波幅
11.00 (17%) — 30.00 (220%)
30.00 (HC Wainwright & Co., 220.51%) 购买
17.00 (81.62%)
11.00 (Barclays, 17.52%) 保留
平均值 17.43 (86.22%)
总计 6 购买, 1 保留
平均价格@调整类型 9.59
公司 日期 目标价格 调整类型 价格@调整类型
RBC Capital 30 Jun 2025 13.00 (38.89%) 购买 9.36
06 May 2025 13.00 (38.89%) 购买 10.27
Wedbush 30 Jun 2025 18.00 (92.31%) 购买 9.36
Needham 27 Jun 2025 17.00 (81.62%) 购买 9.36
25 Jun 2025 17.00 (81.62%) 购买 9.74
Barclays 07 May 2025 11.00 (17.52%) 保留 10.08
HC Wainwright & Co. 06 May 2025 30.00 (220.51%) 购买 10.27
JP Morgan 06 May 2025 13.00 (38.89%) 购买 10.27
Cantor Fitzgerald 29 Apr 2025 20.00 (113.68%) 购买 8.44

该时间范围内无数据。

日期 类型 细节
27 Jun 2025 公告 BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million
27 Jun 2025 公告 BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million
16 Jun 2025 公告 BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI
13 Jun 2025 公告 ORLADEYO® (berotralstat) Approved in Colombia
06 Jun 2025 公告 BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries
03 Jun 2025 公告 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Jun 2025 公告 BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology
30 May 2025 公告 BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages
16 May 2025 公告 BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)
14 May 2025 公告 BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years
05 May 2025 公告 BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update
02 May 2025 公告 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 May 2025 公告 BioCryst Appoints Steve Frank to Board of Directors
30 Apr 2025 公告 BioCryst to Present at Upcoming Investor Conferences
21 Apr 2025 公告 BioCryst to Report First Quarter 2025 Financial Results on May 5
04 Apr 2025 公告 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Apr 2025 公告 BioCryst to Present at Upcoming Investor Conference
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票